In this thesis, the outline and the results of the fi rst part of the Peripheral
Neuropathy outcome measures Standardisation (PeriNomS) study are described.
The PeriNomS study aims to improve and standardise the assessment of patients
with immune-mediated neuropathies. These disorders are potentially treatable
with immuno-modulating agents, therefore, proper outcome measures are needed
to detect clinically important improvement or deterioration over time.
Immune-mediated neuropathies include Guillain-Barré syndrome (GBS), chronic
infl ammatory demyelinating polyneuropathy (CIDP), polyneuropathy associated
with monoclonal gammopathy of undetermined signifi cance (MGUSP), and
multifocal motor neuropathy (MMN). Electrophysiological examination in these
patients generally reveals features of a demyelinating polyneuropathy, although a
subgroup of GBS patients may have predominantly axonal features (acute motor
axonal neuropathy (AMAN)). Diagnostic criteria for all these neuropathies have
been formulated.1-4 From a clinical, electrophysiological, and immunological
point of view there is increasing evidence that these illnesses represent part of a
continuum, mainly separated by their extent of neuromuscular dysfunction, the
evolution of weakness over time, and their response to treatment (table 1). In the
following, a brief overview of these neuropathies is given with particular emphasis
on their clinical presentation.
http://repub.eur.nl/res/pub/30811/120111_Nes%2C%20Sonja%20Ingrid%20van.pdf
No comments:
Post a Comment